- Home
- TCRX vs PARK Comparison
TCRX vs PARK Comparison
Compare TCRX & PARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.03
N/A
Current Price
$14.25
Company Overview
Basic Information| Metric | TCRX | PARK |
|---|---|---|
| Founded | 2018 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 67.5M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TCRX | PARK |
|---|---|---|
| Price | $1.03 | $14.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 823.7K | 124.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.18 |
| EPS | N/A | ★ 2.91 |
| Revenue | $8,423,000.00 | ★ $240,209,000.00 |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.84 |
| Revenue Growth | N/A | ★ 7.47 |
| 52 Week Low | $0.91 | $9.53 |
| 52 Week High | $3.43 | $17.84 |
Technical Indicators
Market Signals| Indicator | TCRX | PARK |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | N/A |
| Support Level | $0.99 | N/A |
| Resistance Level | $1.09 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 35.71 | 0.00 |
Price Performance
Historical Comparison TCRX
PARK
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.